Oral Losartan in Prevention of Post-ERCP Paancreatitis

Summary

Oral losartan given in the dose of 50 mg one hour before ERCP was studied in the prevention of post ERCP pancreatitis in 50 patients indicated for ERCP in comparison with another 50 patients underwent ERCP without receiving oral losartan.

Timeline

Start

2015-01

Primary completion

2017-01

Completion

2017-03

Drugs

Indications